S&P 500 slips, but losses kept in check as Nvidia climbs ahead of results
Aimfinity Investment Corp. I (AIMUF), currently valued at $48.49 million in market capitalization, announced Wednesday that it has entered into agreements with its IPO underwriters to modify their deferred compensation arrangements ahead of its pending business combination with Docter Inc. According to InvestingPro data, the company’s stock has declined 22.66% year-to-date, reflecting market uncertainty around the transaction.
Under the new agreements signed June 13, underwriters D. Boral (OTC:BOALY) Capital LLC and US Tiger Securities will each receive $80,000 in cash plus 132,875 ordinary shares of the post-merger company at closing, instead of their original $2.8 million cash deferred commission. This restructuring comes as InvestingPro analysis indicates a WEAK financial health score of 1.7, suggesting the company may be prioritizing cash preservation.
The agreements include price protection mechanisms that would provide additional shares or cash if the stock trades below the agreed $10 per share value when a registration statement for these shares is filed. The underwriter shares will be registered within 30 days after the business combination closes.
The company also provided an update on its pro forma financial position, estimating shareholders’ equity of approximately $4.02 million as of June 30, 2025, after accounting for redemptions of 1,072,957 shares and various debt conversions. CEO I-Fa Chang will convert approximately $2.6 million in extension and working capital loans into equity at closing.
The business combination with Docter Inc., which was approved by shareholders on March 27, involves a reincorporation merger and acquisition merger. The transaction includes additional equity issuances to settle various outstanding obligations.
The agreements with the underwriters will only take effect if the business combination with Docter is completed.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.